Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Photo

John Moloney and Tracy Woody announced as non-executive Board members

March 7th 2022November 10th 2020

Read More

Photo

Shorla speak with Dr. Scott Gottlieb, 23rd FDA Commissioner

March 7th 2022October 9th 2020

Read More

Shorla Oncology

SH-110 Successful FDA Pre-IND Meeting

March 7th 2022October 2nd 2020

Read More

Photo

Shorla Oncology named Local Enterprise of the Year at The Irish Times Business Awards 2020

March 7th 2022September 3rd 2020

Read More

Banner

Shorla Oncology closes $8.3M Series A funding round

March 7th 2022June 6th 2020

Read More

Banner

Manufacture of first GMP batch of SH-111

March 7th 2022May 11th 2020

Read More

photo

University City Science Center Bootcamp, Philadelphia, USA

March 7th 2022February 14th 2020

Read More

Photo

Worldwide Association of MBA’s Best Entrepreneurial Venture Award (Private Sector) 2020

April 15th 2021February 7th 2020

Read More

photo

J.P. Morgan Annual Healthcare Conference, San Francisco, USA

March 7th 2022January 10th 2020

Read More

Older posts
Newer posts
Page1 … Page9 Page10 Page11 Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.